Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2010

View Archived Issues

Novel mixed-format HIV vaccine shows promise in phase I trial in healthy adult volunteers

Antares and Population Council report phase II trial results for transdermal contraceptive gel

Savient presents update on BLA resubmission for Krystexxa for chronic gout

Novartis launches Fanapt in the U.S. for schizophrenia

PhotoMedex and Galderma Laboratories sign copromotion agreement for Metvixia for AK

Ablynx generates Nanobodies against an ion channel and CXCR4 receptor

Amarin initiates enrollment into MARINE and ANCHOR phase III trials of AMR-101

BioMarin initiates phase I clinical trial of SMT-C1100 for Duchenne muscular dystrophy

Inhibitex presents update on development of SA3Ag vaccine, FV-100 and INX-189

NicOx and Topigen terminate collaboration on anti-inflammatory drug TPI-1020

ReNeuron presents regulatory update on ReN-001 and ReN-009 stem cell therapies

Preclinical findings encourage clinical evaluation of mAb 1339 in multiple myeloma

Milk thistle extract silibinin shows potent activity in in patients with hepatitis C

Synthetic platelets show promise in rat model of major trauma

INX-189 displays potent inhibitory activity against HCV in vitro

Boehringer Ingelheim identifies novel MMP-13 inhibitors as potential arthritis therapeutics

Korea Research Institute of Chemical Technology discloses protein kinase inhibitors for cancer

Novel liver X receptor ligands disclosed by Organon Laboratories as atherosclerosis treatments

Array BioPharma describes novel kinase-inhibiting pyrrolopyridines as oncolytic agents

TaiGen Biotechnology claims novel HCV protease inhibitors

Facet Biotech enrolls first patient in phase II trial of elotuzumab in multiple myeloma

4SC treats first patient in a phase II trial of resminostat in Hodgkin's lymphoma

Cytokinetics reports data from phase I trial of skeletal muscle activator CK-2017357

Pluristem Therapeutics reports interim phase I results on PLX-PAD for critical limb ischemia

KemPharm presents encouraging results from phase I trial of KP-106 for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...